リンパ器官系

-ヘルペスウイルス再活性化〜特に扁桃のリンパ腫がDLBCLならばEBV陽性？
-胃のリンパ腫は生検でスパイク陽性
-リンパ節腫大は菊池・藤本病？
-脾臓のスパイク陽性血管への自己攻撃
-消化管リンパ装置、特に虫垂炎↑

Fantastic 2-day discussion on new strategies in DLBCL with colleagues and friends from Brazil! Hôpital Saint-Louis AP-HP Institut du Cancer AP-HP. Nord Université Paris Cité

Bizarre but cute looking lymphoma cell. No it’s not ATLL. Just another DLBCL.

ルシファーと118D27を復習。非ホジキンリンパ腫は悪性度で治療方針が変わるので覚えましょうってネタです。B細胞のCD20が陽性のためFLとDLBCLで選択です。

バーキットリンパ腫なんかは選択肢としても国試久しぶりな気がします。highly aggressiveで高悪性度としても知られてます。…

Press release: Overall Survival advantage for R-GemOx + glofitamab versus R-GemOx in relapsed DLBCL in patients not fit for autologous transplant. The STARGLO study.
Good to see a DLBCL study with OS as the primary EP.
Keen to see the data!
#lymsm

gene.com/media/press-re….

Welcoming Alan Skarbnik soon at the First annual #HemOnc Pulse live meeting #HOPLive24 Blood Cancers Today where he will be a panelist at the DLBCL, CLL, and CART sessions addressing 'Unanswered Questions' in these disciplines.

Follow here for more updates soon. Countdown starting.

#Bispecifics in DLBCL: When & how?
In earlier lines?
In combination?
Combined with chemo vs other immunotherapy?
Diff Ag targets?
Ag loss?
T cell exhaustion
Randomised studies req re impact on PFS/OS
CRS management strategies better defined
Lorenzo Falchi
#MSKlymphomaCME

DLBCLに関する研究会に出席しました。最近話題のCRSやICANS発生時に安全に対応するための当院総合診療科重症チームとのコラボレーション（いつも大変お世話になり感謝です🙇‍♂️）について、当科スタッフが発表を行いました！

Join us now - Update on #DLBCL Classification webinar
Nathalie Johnson Margaret Shipp Laura Hilton Laura Hilton, PhD
Laurie Sehn Mariana Bastos, MD, PhD
🔗us06web.zoom.us/webinar/regist…

#ADCTherapeutics Bristol Myers Squibb Lymphoma Australia

Last talk of the session is Oscar Atkins from The Crick talking about #DLBCL

ABC and GCB subtype sinonasal DLBCL are geno- and phenotypically distinct entities, exhibiting a contrasting disease course and prognosis. ow.ly/lFOO50Rmt9n #lymphoidneoplasia

Fantastic talk by Marco Ruella on CAR-T - Kate Cwynarski
UCLH Marco Ruella

#Cancer #DLBCL #Lymphodepletion #OncoDaily #Oncology

oncodaily.com/blog/58371.html

Will Townsend: Longer FU if glofit in R/R DLBCL:
• 40% CMR
• DOCR impressive
• 18mo PFS if in CR at EOT 66%
• CR & DOCR similar in post CAR
• use dex as pre-med
• MTV predicts response & tox
#BSH24

🚨🚨🚨 HOT OFF THE PRESS!

⁦Mariana Bastos, MD, PhD⁩: New therapies for relapsed or refractory aggressive B-cell #lymphoma #DLBCL increase survival: Analysis from the #RELINF registry of the GELTAMO⁩ group

#lymsm #hematology

onlinelibrary.wiley.com/doi/10.1002/he…

Closing this session we have Dr Oscar Atkins discussing #DLBCL Oscar Atkins The Crick #YoungEHA #BSH2024

Grand rounds by #LaurieSehn Women In Lymphoma - [email protected]

MSK Department of Medicine MSK CME
#MSKLymphomaCME #lymsm

-many thoughtful trials ongoing in 1L DLBCL
-biology based tx arms are promising
-RR DLBCL has diff biology based on timing of relapse
CART still remains ‘designer therapy’ globally

Given that surface CD79B correlated with sensitivity, we performed CD79B targeted whole genome CRISPR-Cas9 screens in 9 DLBCL cell lines

According to a Genentech press releases: pola GemOx has a better OS compared to R-GemOx in rr DLBCL who ineligible for ASCT.

gene.com/media/press-re…

Fantastic talk Marco Ruella
#CAR -T in #DLBCL
Great science exploring resistance mechanisms
but also
Access to CAR-T in minority health populations? - interesting insights on strategies to address disparities
&
⬇️Toxicity via diff lymphodepletion approaches
#MSKlymphomaCME